Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?

Gunther, Jillian R.; Pinnix, Chelsea C.; Glober, Gordon; Christopherson, Kaitlin M.; Fang, Penny; Lee, Hun Ju; Ahmed, Sairah; Steiner, Raphaël; Nair, Ranjit; Neelapu, Sattva S.; Nastoupil, Loretta J.; Dabaja, Bouthaina S.

doi:10.1002/jha2.1

Cited by 5 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A positive interim PET can direct early treatment intensification to improve prognosis ( Eichenauer et al, 2018 , Ansell, 2020 ). A negative interim PET can lead to de-escalation strategies to minimize treatment-related toxicity with no negative impact on outcome ( Ansell, 2020 , Gunther et al, 2020 ). In our case, interim PET-CT was replaced by WB-DWI/MRI.…”

Section: Discussionmentioning

confidence: 99%

Pushing the boundaries. Concurrent Hodgkin lymphoma and breast cancer treatment with preservation of pregnancy: A case report

Charlotte

Dierickx

Wildiers

et al. 2022

Gynecologic Oncology Reports

View full text Add to dashboard Cite

Highlights This is the first reported case of two concurrent primary cancers during pregnancy. The multidisciplinary tumor board was critical in defining the best treatment. Modifications to the standard-of-care should always be motivated. Both cancers were treated during pregnancy with surgery and chemotherapy. The result was a good maternal and obstetric outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Pushing the boundaries. Concurrent Hodgkin lymphoma and breast cancer treatment with preservation of pregnancy: A case report

Charlotte

Dierickx

Wildiers

et al. 2022

Gynecologic Oncology Reports

View full text Add to dashboard Cite

show abstract

“…Gunther et al demonstrated that partial omission of bleomycin resulted in a 99% freedom from relapse at 8 years. 21…”

Section: Elderly Hodgkin Lymphomamentioning

confidence: 99%

Management of limited stage Hodgkin lymphoma

Kodad¹

2023

Can Hematol Today

View full text Add to dashboard Cite

Hodgkin lymphoma (HL) is a lymphoid neoplasm characterized by malignant lymphocytes, known as Reed-Sternberg cells, on a background of non-neoplastic inflammatory cells. Lugano staging determines the stage of Hodgkin lymphoma, which, in turn, determines the treatment and prognosis. Limited-stage disease is defined as Stage I and Stage II, which is diagnosed in more than 50% of patients. Pre-treatment risk stratification, PET-adapted therapy, and combined modality treatment have significantly improved cure rates, making limited-stage HL one of the most curable malignancies. In this article, we discuss the current approach to managing limited-stage HL.

show abstract

“…Finally, a diagnosis of classical Hodgkin lymphoma – mixed cellularity (Lugano II) was established. The patient received 4 cycles of AVD (adriamycin, vinblastine, dacarbazine; bleomycin was omitted due to patient age) chemotherapy 5 and attained complete metabolic remission confirmed by PET-FDG. DA was continued during treatment at a reduced dose of 50 mg except on chemotherapy days.…”

Section: Case Reportmentioning

confidence: 99%

Hodgkin Lymphoma as a Secondary Neoplasm During Therapy for Chronic Myeloid Leukaemia: Case Report and Review of the Literature

Paczkowska

Janowski

Karpińska-Kaczmarczyk

et al. 2021

OTT

View full text Add to dashboard Cite

Introduction Incidences of chronic myeloid leukaemia (CML) after treatment of Hodgkin lymphoma (HL) are well described. Here, we report a case of secondary HL in a patient with CML treated with dasatinib as a third-line treatment. Patient Information A 64-year-old male was diagnosed with CML and initially treated with imatinib and then with nilotinib due to resistance. Finally, the patient experienced cardiovascular complications, and dasatinib was introduced. After 19 months of treatment, the patient experienced enlargement of lymph nodes that formed packs on the neck. Interventions Based on histopathological examination of the lymph nodes, a diagnosis of classical Hodgkin lymphoma – mixed cellularity was established. The patient was successfully treated with 4 cycles of AVD (adriamycin, vinblastine, dacarbazine) chemotherapy. Outcomes Complete metabolic remission of Hodgkin lymphoma is currently sustained, and the molecular response to dasatinib at a reduced dose of 50 mg daily corresponds with a deep molecular response. Conclusion In this report, we demonstrate the efficacy and safety of the combination of dasatinib and AVD regimens in coexisting CML and HL. This case report emphasizes the importance of insightful evaluation and differential diagnosis in cases of lymphadenopathy during CML treatment.

show abstract

Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?

Cited by 5 publications

References 11 publications

Pushing the boundaries. Concurrent Hodgkin lymphoma and breast cancer treatment with preservation of pregnancy: A case report

Pushing the boundaries. Concurrent Hodgkin lymphoma and breast cancer treatment with preservation of pregnancy: A case report

Management of limited stage Hodgkin lymphoma

Hodgkin Lymphoma as a Secondary Neoplasm During Therapy for Chronic Myeloid Leukaemia: Case Report and Review of the Literature

Contact Info

Product

Resources

About